Skip to main content
Top

Open Access 30-09-2024 | Migraine | ORIGINAL RESEARCH

A Discrete-Choice Experiment Assessing the Patient Preferences and Real-World Experiences of Patients with Migraine in Japan

Authors: Takao Takeshima, Akira Yuasa, Yukie Michelle Lloyd, Louis Patrick Watanabe, Kazumasa Kamei, Akiho Terasawa, Josh Coulter, Lucy Abraham, Brett Hauber, Masahiro Iijima

Published in: Neurology and Therapy

Login to get access

Abstract

Introduction

Migraine is a debilitating headache disorder with a high prevalence in Japan that imposes significant societal burden. Although the Japanese Clinical Practice Guideline for Headache Disorders 2021 recommends both acute and preventive migraine treatments, the usage of preventive treatments is still limited. Therefore, it is crucial to understand the treatment preferences of patients with migraine pertaining to both acute and preventive treatments.

Methods

A mixed-methods study including a discrete choice experiment (DCE) was conducted with Japanese patients with migraine (10 for the qualitative interviews, and 400 for the DCE) who were recruited from the Rakuten Insight panel. The DCE presented hypothetical treatment options including oral acute, oral preventive, and injectable preventive medications. Six attributes (method of delivery, reduction of pain, impact of headaches on daily routines, dosage adjustability, and temporary and persistent side effects) each with three levels were included in the survey. A hierarchical Bayesian model was used to estimate relative attribute importance scores (RAI) for all attributes.

Results

For the 400 participants in the DCE, the most common age bracket was 40–49 years old, and the majority were female (66.75%). RAI estimates indicated that “method of delivery” was the most important attribute for patients (RAI 51.92, SD = 10.20), followed by “reduction of pain when experiencing a headache” (RAI 17.00, SD = 7.74). Oral preventive treatments were preferred over injectable preventive treatments. The qualitative interviews showed that patients prefer oral medications to injectable treatments, and a lack of awareness regarding preventive treatments.

Conclusion

This study found that the “method of delivery” was the most important driver of treatment preferences of patients with migraine in Japan, with oral acute medications being preferred. Oral preventive treatments were found to be preferred over injectable treatments. These results may indicate the need for increased education regarding preventive treatments, as well as the need for further development of these treatments.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37:1945–55.CrossRefPubMed Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37:1945–55.CrossRefPubMed
2.
go back to reference Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20:111.CrossRefPubMedPubMedCentral Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20:111.CrossRefPubMedPubMedCentral
3.
go back to reference Klan T, Bräscher AK, Klein S, et al. Assessing attack-related fear in headache disorders—structure and psychometric properties of the fear of attacks in migraine inventory. Headache. 2022;62:294–305.CrossRefPubMed Klan T, Bräscher AK, Klein S, et al. Assessing attack-related fear in headache disorders—structure and psychometric properties of the fear of attacks in migraine inventory. Headache. 2022;62:294–305.CrossRefPubMed
4.
go back to reference Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17:15–22.CrossRefPubMed Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17:15–22.CrossRefPubMed
5.
go back to reference Takeshima T, Ishizaki K, Fukuhara Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44:8–19.CrossRefPubMed Takeshima T, Ishizaki K, Fukuhara Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44:8–19.CrossRefPubMed
6.
go back to reference Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60–8.CrossRefPubMed Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60–8.CrossRefPubMed
7.
go back to reference Takeshima T, Ueda K, Komori M, et al. Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) Study. Adv Ther. 2022;39:5176–90.CrossRefPubMedPubMedCentral Takeshima T, Ueda K, Komori M, et al. Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) Study. Adv Ther. 2022;39:5176–90.CrossRefPubMedPubMedCentral
10.
go back to reference Chaudhari K, Syed BA. The pipeline and market for migraine drugs. Nat Rev Drug Discov. 2024;23:246–7.CrossRefPubMed Chaudhari K, Syed BA. The pipeline and market for migraine drugs. Nat Rev Drug Discov. 2024;23:246–7.CrossRefPubMed
12.
go back to reference Xu X, Ji Q, Shen M. Patient preferences and values in decision making for migraines: a systematic literature review. Pain Res Manage. 2021;2021:9919773.CrossRef Xu X, Ji Q, Shen M. Patient preferences and values in decision making for migraines: a systematic literature review. Pain Res Manage. 2021;2021:9919773.CrossRef
14.
go back to reference Soekhai V, Whichello C, Levitan B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discovery Today. 2019;24:1324–31.CrossRefPubMed Soekhai V, Whichello C, Levitan B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discovery Today. 2019;24:1324–31.CrossRefPubMed
15.
go back to reference Palinkas LA, Aarons GA, Horwitz S, et al. Mixed method designs in implementation research. Adm Policy Ment Health. 2011;38:44–53.CrossRefPubMed Palinkas LA, Aarons GA, Horwitz S, et al. Mixed method designs in implementation research. Adm Policy Ment Health. 2011;38:44–53.CrossRefPubMed
16.
go back to reference Seo J, Tervonen T, Ueda K, et al. Discrete choice experiment to understand Japanese patients’ and physicians’ preferences for preventive treatments for migraine. Neurol Ther. 2023;12:651–68.CrossRefPubMedPubMedCentral Seo J, Tervonen T, Ueda K, et al. Discrete choice experiment to understand Japanese patients’ and physicians’ preferences for preventive treatments for migraine. Neurol Ther. 2023;12:651–68.CrossRefPubMedPubMedCentral
17.
go back to reference Schwedt TJ, Martin A, Kymes S, et al. Patient preferences for attributes of injected or infused preventive migraine medications: findings from a discrete choice experiment. Headache. 2023;63:484–93.CrossRefPubMed Schwedt TJ, Martin A, Kymes S, et al. Patient preferences for attributes of injected or infused preventive migraine medications: findings from a discrete choice experiment. Headache. 2023;63:484–93.CrossRefPubMed
18.
go back to reference Hubig LT, Smith T, Chua GN, et al. A stated preference survey to explore patient preferences for novel preventive migraine treatments. Headache. 2022;62:1187–97.CrossRefPubMedPubMedCentral Hubig LT, Smith T, Chua GN, et al. A stated preference survey to explore patient preferences for novel preventive migraine treatments. Headache. 2022;62:1187–97.CrossRefPubMedPubMedCentral
19.
go back to reference Torbica A, Rognoni C, Tarricone R. Investigating patients’ preferences to inform drug development decisions: novel insights from a discrete choice experiment in migraine. Int J Environ Res Public Health. 2021;18:4916.CrossRefPubMedPubMedCentral Torbica A, Rognoni C, Tarricone R. Investigating patients’ preferences to inform drug development decisions: novel insights from a discrete choice experiment in migraine. Int J Environ Res Public Health. 2021;18:4916.CrossRefPubMedPubMedCentral
20.
go back to reference Mansfield C, Gebben DJ, Sutphin J, et al. Patient preferences for preventive migraine treatments: a discrete-choice experiment. Headache. 2019;59:715–26.CrossRefPubMed Mansfield C, Gebben DJ, Sutphin J, et al. Patient preferences for preventive migraine treatments: a discrete-choice experiment. Headache. 2019;59:715–26.CrossRefPubMed
21.
22.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2-assessing respondent understanding. Value Health. 2011;14:978–88.CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2-assessing respondent understanding. Value Health. 2011;14:978–88.CrossRefPubMed
25.
go back to reference Hauber AB, González JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19:300–15.CrossRefPubMed Hauber AB, González JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19:300–15.CrossRefPubMed
27.
go back to reference Ishii R, Schwedt TJ, Dumkrieger G, et al. Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache. 2021;61:992–1003.CrossRefPubMed Ishii R, Schwedt TJ, Dumkrieger G, et al. Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache. 2021;61:992–1003.CrossRefPubMed
28.
go back to reference Matsumori Y, Ueda K, Komori M, et al. Burden of migraine in Japan: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan]) study. Neurol Ther. 2022;11:205–22.CrossRefPubMed Matsumori Y, Ueda K, Komori M, et al. Burden of migraine in Japan: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan]) study. Neurol Ther. 2022;11:205–22.CrossRefPubMed
29.
go back to reference Takizawa T, Kitano T, Iijima M, Togo K, Yonemoto N. Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. J Headache Pain. 2024;25:19.CrossRefPubMedPubMedCentral Takizawa T, Kitano T, Iijima M, Togo K, Yonemoto N. Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. J Headache Pain. 2024;25:19.CrossRefPubMedPubMedCentral
30.
go back to reference Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64:333–41.CrossRefPubMed Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64:333–41.CrossRefPubMed
Metadata
Title
A Discrete-Choice Experiment Assessing the Patient Preferences and Real-World Experiences of Patients with Migraine in Japan
Authors
Takao Takeshima
Akira Yuasa
Yukie Michelle Lloyd
Louis Patrick Watanabe
Kazumasa Kamei
Akiho Terasawa
Josh Coulter
Lucy Abraham
Brett Hauber
Masahiro Iijima
Publication date
30-09-2024
Publisher
Springer Healthcare
Keywords
Migraine
Headache
Published in
Neurology and Therapy
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-024-00663-0

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more